TY - JOUR
T1 - Age at onset and Parkinson disease phenotype
AU - Pagano, Gennaro
AU - Ferrara, Nicola
AU - Brooks, David J.
AU - Pavese, Nicola
N1 - Cited By :2
Export Date: 30 July 2016
References: Lewis, S.J., Foltynie, T., Blackwell, A.D., Robbins, T.W., Owen, A.M., Barker, R.A., Heterogeneity of Parkinsons disease in the early clinical stages using a data driven approach (2005) J Neurol Neurosurg Psychiatry, 76, pp. 343-348; Eggers, C., Pedrosa, D.J., Kahraman, D., Parkinson subtypes progress differently in clinical course and imaging pattern (2012) PLoS One, 7, p. e46813; Selikhova, M., Williams, D.R., Kempster, P.A., Holton, J.L., Revesz, T., Lees, A.J., A clinico-pathological study of subtypes in Parkinsons disease (2009) Brain, 132, pp. 2947-2957; Parkkinen, L., Osullivan, S.S., Collins, C., Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinsons disease (2011) J Parkinsons Dis, 1, pp. 277-286; Pringsheim, T., Jette, N., Frolkis, A., Steeves, T.D., The prevalence of Parkinsons disease: A systematic review and meta-analysis (2014) Mov Disord, 29, pp. 1583-1590; Kish, S.J., Shannak, K., Rajput, A., Deck, J.H., Hornykiewicz, O., Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinsons disease (1992) J Neurochem, 58, pp. 642-648; De Lau, L.M., Breteler, M.M., Epidemiology of Parkinsons disease (2006) Lancet Neurol, 5, pp. 525-535; Kempster, P.A., Osullivan, S.S., Holton, J.L., Revesz, T., Lees, A.J., Relationships between age and late progression of Parkinsons disease: A clinico-pathological study (2010) Brain, 133, pp. 1755-1762; Critchley, M., The neurology of old age (1931) Lancet, 1, pp. 1221-1230; Wickremaratchi, M.M., Ben-Shlomo, Y., Morris, H.R., The effect of onset age on the clinical features of Parkinsons disease (2009) Eur J Neurol, 16, pp. 450-456; Quinn, N., Critchley, P., Marsden, C.D., Young onset Parkinsons disease (1987) Mov Disord, 2, pp. 73-91; Gomez Arevalo, G., Jorge, R., Garcia, S., Scipioni, O., Gershanik, O., Clinical and pharmacological differences in early- versus late-onset Parkinsons disease (1997) Mov Disord, 12, pp. 277-284; Wickremaratchi, M.M., Perera, D., Ologhlen, C., Prevalence and age of onset of Parkinsons disease in Cardiff: A community based cross sectional study and meta-analysis (2009) J Neurol Neurosurg Psychiatry, 80, pp. 805-807; Schrag, A., Ben-Shlomo, Y., Brown, R., Marsden, C.D., Quinn, N., Young-onset Parkinsons disease revisited clinical features, natural history, and mortality (1998) Mov Disord, 13, pp. 885-894; Golbe, L.I., Young-onset Parkinsons disease: A clinical review (1991) Neurology, 41, pp. 168-173; Wickremaratchi, M.M., Knipe, M.D., Sastry, B.S., The motor phenotype of Parkinsons disease in relation to age at onset (2011) Mov Disord, 26, pp. 457-463; Mehanna, R., Moore, S., Hou, J.G., Sarwar, A.I., Lai, E.C., Comparing clinical features of young onset, middle onset and late onset Parkinsons disease (2014) Parkinsonism Relat Disord, 20, pp. 530-534; Szewczyk-Krolikowski, K., Tomlinson, P., Nithi, K., The influence of age and gender on motor and non-motor features of early Parkinsons disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort (2014) Parkinsonism Relat Disord, 20, pp. 99-105; The Parkinson Progression Marker Initiative (PPMI) (2011) Prog Neurobiol, 95, pp. 629-635. , Parkinson Progression Marker Initiative; Post, B., Speelman, J.D., De Haan, R.J., Clinical heterogeneity in newly diagnosed Parkinsons disease (2008) J Neurol, 255, pp. 716-722. , CARPA-study group; Kang, J.H., Irwin, D.J., Chen-Plotkin, A.S., Al, E., Association of cerebrospinal fluid b-amyloid 1-42, T-tau, P-tau181, and a-synuclein levels with clinical features of drug-naive patients with early Parkinson disease (2013) JAMA Neurol, 70, pp. 1277-1287. , Parkinsons Progression Markers Initiative; Berg, D., Postuma, R.B., Bloem, B., Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinsons disease (2014) Mov Disord, 29, pp. 454-462; Marras, C., Lang, A., Parkinsons disease subtypes: Lost in translation? (2013) J Neurol Neurosurg Psychiatry, 844, pp. 409-415; Van Der Hoorn, A., Burger, H., Leenders, K.L., De Jong, B.M., Handedness correlates with the dominant Parkinson side: A systematic review and meta-analysis (2012) Mov Disord, 27, pp. 206-210; De La Fuente-Fernández, R., Kishore, A., Calne, D.B., Ruth, T.J., Stoessl, A.J., Nigrostriatal dopamine system and motor lateralization (2000) Behav Brain Res, 112, pp. 63-68; Vidailhet, M., Bonnet, A.M., Marconi, R., Gouider-Khouja, N., Agid, Y., Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? (1994) Neurology, 44, pp. 1613-1616; Dickson, J.M., Grunewald, R.A., Somatic symptom progression in idiopathic Parkinsons disease (2004) Parkinsonism Relat Disord, 10, pp. 487-492; Rowland, T., Chan, H.C., Brooks, D.J., Pavese, N., Progression of nigrostriatal projection functional loss through the striatum in Parkinsons disease: A clinico-PET correlation (2013) MDS 17th International Congress of Parkinsons Disease and Movement Disorders, 28. , June Abstract Supplement; Yurkovich, M., Avina-Zubieta, J.A., Thomas, J., Gorenchtein, M., Lacaille, D., A systematic review identifies valid comorbidity indices derived from administrative health data (2015) J Clin Epidemiol, 68, pp. 3-14
PY - 2016/4/12
Y1 - 2016/4/12
N2 - Objective: To explore clinical phenotype and characteristics of Parkinson disease (PD) at different ages at onset in recently diagnosed patients with untreated PD. Methods: We have analyzed baseline data from the Parkinson's Progression Markers Initiative database. Four hundred twenty-two patients with a diagnosis of PD confirmed by DaTSCAN imaging were divided into 4 groups according to age at onset (onset younger than 50 years, 50-59 years, 60-69 years, and 70 years or older) and investigated for differences in side, type and localization of symptoms, occurrence/severity of motor and nonmotor features, nigrostriatal function, and CSF biomarkers. Results: Older age at onset was associated with a more severe motor and nonmotor phenotype, a greater dopaminergic dysfunction on DaTSCAN, and reduction of CSF α-synuclein and total tau. The most common presentation was the combination of 2 or 3 motor symptoms (bradykinesia, resting tremor, and rigidity) with rigidity being more common in the young-onset group. In about 80% of the patients with localized onset, the arm was the most affected part of the body, with no difference across subgroups. Conclusions: Although the presentation of PD symptoms is similar across age subgroups, the severity of motor and nonmotor features, the impairment of striatal binding, and the levels of CSF biomarkers increase with age at onset. The variability of imaging and nonimaging biomarkers in patients with PD at different ages could hamper the results of future clinical trials.
AB - Objective: To explore clinical phenotype and characteristics of Parkinson disease (PD) at different ages at onset in recently diagnosed patients with untreated PD. Methods: We have analyzed baseline data from the Parkinson's Progression Markers Initiative database. Four hundred twenty-two patients with a diagnosis of PD confirmed by DaTSCAN imaging were divided into 4 groups according to age at onset (onset younger than 50 years, 50-59 years, 60-69 years, and 70 years or older) and investigated for differences in side, type and localization of symptoms, occurrence/severity of motor and nonmotor features, nigrostriatal function, and CSF biomarkers. Results: Older age at onset was associated with a more severe motor and nonmotor phenotype, a greater dopaminergic dysfunction on DaTSCAN, and reduction of CSF α-synuclein and total tau. The most common presentation was the combination of 2 or 3 motor symptoms (bradykinesia, resting tremor, and rigidity) with rigidity being more common in the young-onset group. In about 80% of the patients with localized onset, the arm was the most affected part of the body, with no difference across subgroups. Conclusions: Although the presentation of PD symptoms is similar across age subgroups, the severity of motor and nonmotor features, the impairment of striatal binding, and the levels of CSF biomarkers increase with age at onset. The variability of imaging and nonimaging biomarkers in patients with PD at different ages could hamper the results of future clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=84964845283&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002461
DO - 10.1212/WNL.0000000000002461
M3 - Article
AN - SCOPUS:84964845283
SN - 0028-3878
VL - 86
SP - 1400
EP - 1407
JO - Neurology
JF - Neurology
IS - 15
ER -